Last reviewed 2026-05-30 · How we verify

T-reg depleted DLI

Assistance Publique - Hôpitaux de Paris · Phase 1 active Small molecule ✓ Verified May 2026

T-reg depleted DLI is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development.

Researchers are studying T-reg depleted DLI as a treatment for hematological malignancies, relapse, and chronic graft versus host disease. The treatment involves depleting regulatory T cells from donor lymphocytes before administering them to patients.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	T-reg depleted DLI
Sponsor	Assistance Publique - Hôpitaux de Paris
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

T-reg depleted DLI CI brief — competitive landscape report
T-reg depleted DLI updates RSS · CI watch RSS
Assistance Publique - Hôpitaux de Paris portfolio CI

Frequently asked questions about T-reg depleted DLI

What is T-reg depleted DLI?

T-reg depleted DLI is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes T-reg depleted DLI?

T-reg depleted DLI is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What development phase is T-reg depleted DLI in?

T-reg depleted DLI is in Phase 1.

Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing